Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Byetta Prescribers for Diabetes: Endocrinologists (US)

Council Members in this Study Group: 126

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Harold Bays, President and Medical Director, L-MARC Research CenterHarold Bays

President and Medical Director
L-MARC Research Center
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Harold Bays, MD, FACP, FACE, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all...

Dan Streja

Clinical Professor of Medicine
UNIVERSITY OF CALIFORNIA, LOS ANGELES
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA...

Farhad Zangeneh, Assistant Clinical Professor of Medicine , THE GEORGE WASHINGTON UNIVERSITY - CCFarhad Zangeneh

Assistant Clinical Professor of Medicine
THE GEORGE WASHINGTON UNIVERSITY - CC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Farhad Zangeneh, MD, is an Assistant Clinical Professor of Medicine at George Washington University School of Medicine in District of Columbia. He is on the board of directors of ACCE and recently contributed to the AACE Diabetes guidelines. He is the...

George Griffing

Director of General Internal Medicine
SAINT LOUIS UNIVERSITY
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

George Griffing, MD, is Professor of Internal Medicine at St. Louis University. Dr. Griffing's clinical expertise includes the diagnosis and treatment of diabetes. His research interests include the clinical investigation of inhaled insulin, nasal insulin...

Michael Dempsey, Medical Director, SUBURBAN HOSPITAL, INCMichael Dempsey

Medical Director
SUBURBAN HOSPITAL, INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Michael Dempsey, MD, is a Private Practitioner in Rockville, Maryland. He is the Medical Director of the Johns Hopkins Diabetes Center at Suburban Hospital, where he is also the Medical Director of Diabetes Education and Endocrine Subsection Chair. He...

GLG NewsSM Analyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Outsourcing of compassionate use of drugs?

January 18, 2008

No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com

The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal illness have traveled outside the US to purchase hope when our management was offering none. Although in the majority of cases the hope was unjustified, the current decision will encourage healthcare providers residing outside the US to advertise for their services through the internet. The issue should be addressed by the legislators sooner rather than later. Drugs who improve quality of life, awaiting approval for survival indication or drugs looking promising in early clinical trials could be made available to dying patients with informed consent addressing our limitations.  

Non-glycemic benefits of Rosigliatazone: too little to late?

July 10, 2006

Rosiglitazone May Delay Progression of Severe Diabetic Retinopathy | www.ophthalmologytimes.com

Reduction of proliferative rentinopathy in patients with Diabetes by Rosigliatzone.

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Private/For-Profit Healthcare Research Entity
  • Other Freestanding Healthcare Facility
  • Academic Institution*

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Partner
  • President
  • Director
  • Physician - Department Chair
  • Medical Director
  • Physician - Division Head